Mesoblast plans to immediately start onboarding transplant centers following the US Food and Drug Administration approval of its allogeneic cell therapy Ryoncil (remestemcel-L) for pediatric patients with steroid-refractory acute graft versus host disease (SR-aGVHD), after it was the subject of two complete response letters (CRL) from the agency.
Mesoblast Finally Gets FDA Nod For Ryoncil
The cell therapy won approval for pediatric steroid-refractory acute graft versus host disease after two complete response letters over the last four years.
